Shasun Pharmaceuticals, a Rs.1,000 crore pharma giant from Chennai, has registered strong performance during the third quarter ended December 2013 despite significant higher interest cost and its consolidated net profit moved up by 58.8 per cent to Rs.13.04 crore from Rs.8.21 crore in the corresponding period of last year. Its EBDITA also increased by 59.4 per cent to Rs.44.67 crore from Rs.28.02 crore. Its consolidated net sales increased by 20.3 per cent to Rs.300.38 crore from Rs.357.09 crore. With hefty jump in profits, its EPS moved up to Rs 2.30 from Rs 1.49 in the last period.

For the first nine months ended December 2013, Shasun's net sales improved by six per cent to Rs.811 crore from Rs.765 crore in the same period of last year. However, its EBDITA declined by 8.6 per cent to Rs.95.47 crore from Rs.104.44 crore and net profit by 50.2 per cent to Rs.19.81 crore from Rs.39.78 crore. Its interest cost went up by 30.4 per cent to Rs.34.15 crore from Rs.26.10 crore. During the period, it has shown a tax benefit of Rs.10.30 crore as compared to expenses of Rs.1.78 crore in the previous period.